Eidelman Virant Capital’s Evogene EVGN Stock Holding History

Eidelman Virant Capital’s Portfolio EVGN Stock Details EVGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	$96K	Hold	11,700	–	–	0.07%	154
2022 Q2	$101K	Hold	11,700	–	–	0.07%	159
2022 Q1	$152K	Buy	11,700 +400	+4%	+$5.39K	0.08%	160
2021 Q4	$185K	Buy	+11,300	New	+$256K	0.07%	183
2021 Q1	–	Sell	-1,510	Closed	-$71K	–	183
2020 Q4	$71K	Sell	1,510 -3,850	-72%	-$136K	0.03%	167
2020 Q3	$219K	Sell	5,360 -1,100	-17%	-$19.6K	0.12%	118
2020 Q2	$65K	Buy	+6,460	New	+$70.1K	0.05%	116
2019 Q3	–	Sell	-6,360	Closed	-$102K	–	124
2019 Q2	$102K	Buy	+6,360	New	+$118K	0.05%	115
2017 Q3	–	Sell	-3,230	Closed	-$163K	–	109
2017 Q2	$163K	Hold	3,230	–	–	0.09%	94
2017 Q1	$172K	Sell	3,230 -1,540	-32%	-$80.2K	0.12%	89
2016 Q4	$243K	Buy	4,770 +2,840	+147%	+$163K	0.14%	91
2016 Q3	$123K	Sell	1,930 -230	-11%	-$15.1K	0.08%	110
2016 Q2	$135K	Buy	2,160 +50	+2%	+$3.48K	0.08%	117
2016 Q1	$138K	Buy	2,110 +380	+22%	+$26.1K	0.09%	112
2015 Q4	$139K	Buy	+1,730	New	+$129K	0.08%	131

Other funds holding EVGN

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Senvest Management New York $3.01B AUM 35.7% 1-Year Est. Return

SCM

Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

SPC

Sigma Planning Corp Ann Arbor, Michigan $3.6B AUM 24.57% 1-Year Est. Return

CAG

Csenge Advisory Group Clearwater, Florida $2.18B AUM 16.73% 1-Year Est. Return

Eidelman Virant Capital's EVGN Position: Q3 2022 in Review

Eidelman Virant Capital held its Evogene (EVGN) position steady in Q3 2022 at 11,700 shares worth $96K. The position accounts for 0.07% of the portfolio, ranked #154.

Eidelman Virant Capital first reported a position in EVGN in Q4 2015 and has held it in 15 quarters since. The position peaked at $243K in Q4 2016. 26 funds tracked by Wall St. Rank hold EVGN as of Q3 2022.

Eidelman Virant Capital held 11,700 shares of Evogene worth $96K as of Q3 2022.
Eidelman Virant Capital left its Evogene share count unchanged in Q3 2022.
Evogene made up 0.07% of Eidelman Virant Capital's portfolio in Q3 2022, its #154 holding.
Eidelman Virant Capital first reported a position in Evogene in Q4 2015 and has held it in 15 quarters since.
Eidelman Virant Capital's Evogene position peaked at $243K in Q4 2016.
26 funds tracked by Wall St. Rank held Evogene as of Q3 2022.

Based on Eidelman Virant Capital's 13F filing for Q3 2022, filed 25 Oct 2022.